METHODS OF DONOR SPECIFIC CROSSMATCHING

• US 20090142780A1
• Filed: 12/02/2008
• Published: 06/04/2009
• Est. Priority Date: 05/16/2002
• Status: Active Grant

• Current Assignee: Olerup SSP AB (CareDx, Inc.)
• Original Assignee: Absorber AB (CareDx, Inc.)
• Inventors: Holgersson, Suchitra Sumitran
• Granted Patent: US 8,034,635 B2
• Time in Patent Office: Days
• US Class Current: 435/7.210
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders SLE G01N2800/104
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/56966 Animal cells

Abstract

The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating endothelial cell antibodies and methods for donor-specific crossmatching.

Claims

1. A method of cross-matching a donor and a recipient comprising:

(a) providing a donor sample containing, or suspected of containing, an endothelial cell;

(b) contacting the donor sample with a detection reagent to isolate the endothelial cell; and

(c) screening a recipient sample for a reactivity with the isolated endothelial cell wherein no reactivity of the recipient sample with the isolated endothelial cell indicates compatibility between the donor and recipient.

2. The method of claim 1, wherein the detection reagent is a ligand for an endothelial cell surface receptor.

3. The method of claim 2, wherein said ligand is angiopoietin or VEGF.

4. The method of claim 1, wherein the detection reagent is an antibody, or fragment thereof.

5. The method of claim 4, wherein the antibody is specific against an endothelial cell receptor.

6. The method of claim 5, wherein the endothelial cell receptor is Tie-2 or VEGFR-1.

7. The method of claim 1, wherein the isolated endothelial cell is Tie-2 positive or VEGFR-1 positive.

8. The method of claim 1, wherein the donor sample or recipient sample is selected from the group consisting of whole blood, sera, tissue, peripheral blood mononuclear cells, and leucapherisate.

9. The method of claim 1, wherein the endothelial cell is a precursor endothelial cell.

10. The method of claim 4, wherein the antibody or fragment thereof is attached to a solid support.

11. The method of claim 10, wherein the solid support is a non-magnetic, magnetic or a paramagnetic bead.

12. The method of claim 4, wherein the antibody is a Fab fragment.